11/11
09:25 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
11/11
09:25 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
11/7
02:41 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
11/3
08:03 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
10/31
01:39 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/31
01:39 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/31
01:39 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/30
10:40 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $71.00 price target on the stock, up previously from $69.00.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $71.00 price target on the stock, up previously from $69.00.
10/30
10:32 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/30
10:32 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/30
09:44 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
10/27
03:04 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
10/27
03:04 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
10/21
01:50 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
10/21
01:50 pm
bbio
Rating for BBIO
Low
Report
Rating for BBIO
9/15
08:06 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
9/12
10:25 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO